BlinkBio
BlinkBio, a biotech firm, leverages its TDC platform to design innovative cancer therapies using BLink chemistries, founded in 2009 in Florida.
Founded
2009BlinkBio, a biotech firm, leverages its TDC platform to design innovative cancer therapies using BLink chemistries, founded in 2009 in Florida.
BlinkBio, founded in 2009 in Florida, is a biotechnology company dedicated to developing innovative cancer therapies. The company's core mission is to exploit Bioorthogonal Linker (BLink) chemistries through their Tunable Drug Conjugates (TDCs) platform. This platform comprises a modular set of ligands, linkers, and payloads designed to create a new class of drug conjugate therapies for oncology and other diseases. BlinkBio focuses on providing rapid and effective treatment options for cancer patients.
Key figures associated with BlinkBio include its founders and leading scientists in the field of biotechnology. The company has attracted significant attention from investors due to its pioneering approach to cancer treatment. Notable achievements include the successful development of its TDC platform and the assembly of a comprehensive toolbox for drug conjugate design. BlinkBio's impact lies in its potential to revolutionize cancer therapy by offering more targeted and efficient treatment options.
Companies similar to BlinkBio include Blaze Bioscience, TellBio, Bolt Biotherapeutics and Vivacitas Oncology.
BlinkBio was founded in 2009.
BlinkBio's headquarters is located in Jupiter, FL, US.
BlinkBio's most recent funding round was for $525k (USD) in May 2019.
As of May 7, 2019, BlinkBio has disclosed funding of $20.7M (USD). Undisclosed round amounts are excluded.
BlinkBio has 7 employees as of Feb 5, 2024.
Vivacitas Oncology
vivaoncology.com
